Low Dose Naltrexone (LDN) - Off-label use of opioid antagonist Naltrexone drug to treat cancer
Low dose naltrexone (LDN) against cancer
Cancer Core / Also "NON-STAGE IV / Add-On treatment
What is LDN?
Prescribed 'off-label', Naltrexone
(generic name) is a prescription
opioid antagonist drug given at unconventionally low doses
LDN is believed to work against diseases by improving immune function.
By marginally blocking your opioid receptors is believed to up-regulate vital elements
of your immune system by increasing your body's production of metenkephalin and
endorphins (your natural opioids),
For more information on LDN:
Low Dose Naltrexone(LDN) - Immune regulatorfor Auto-Immune Diseases
+ Cancer, AIDS, COPD and the common cold
LDN used against cancers
LDN is used:
As a preventive treatment against cancer
To prevent a recurrence of cancer
To treat cancer - LDN has been shown in many cases
to work with virtually incurable cancers such as neuroblastoma, multiple myeloma,
and pancreatic cancer.
Research on neuropeptide receptors expressed by various
human tumors has found opioid receptors in many types of cancer:
Brain tumors (both astrocytoma and glioblastoma)
Breast cancer
Endometrial cancer
Head and neck squamous cell carcinoma
Myeloid leukemia
Lung cancer (both small cell and non-small cell)
Neuroblastoma
Others...
LDN effects against cancer
Increased endorphin production and other related
factors linked to anti-cancer mechanisms - Dr. Bernard Bihari,
who first discovered LDN as a therapeutic agent for AIDS, in 1985, believes LDNs
anti-cancer mechanism is likely due to an increase in:
▲ Increased endorphins
(morphine-like substances originating from inside the body)
▲ Number and density of opiate
receptors on the tumor cell membrane s - making them more responsive
to the growth-inhibiting effects of the already present levels of endorphins, which
in turn induces apoptosis (cell death) in the cancer cells
▲ The absolute numbers of
circulating cytotoxic T-cells and natural killer cells - as well as
killer cell activity
Dr. Bihari reports promising results in treating
450+ cancer patients with LDN - , including cancers of the bladder,
breast, liver, lung, lymph nodes, colon, and rectum. According to Dr. Bihari, close
to a quarter of his patients had at least a 75% reduction in tumor size, and nearly
60% of his patients demonstrated disease stability.
Dr Ian Zagon has shown in one study that LDN can
stop breast cancer cells growing in multiple resistant breast cancer - by
a mechanism that acts on the 'p21 cyclin-dependent inhibitory kinase pathway, present
in many solid tumors and a large proportion of breast cancers
http://www.sciencedaily.com/releases/2013/08/130810063639.htm
http://ldnresearchtrust.org/sites/default/files/LDN%20Information%20Pack(1).pdf
The Berkson Method is a cancer therapy that combines
LDN and Alpha Lipoic Acid
http://www.anticancer.org.uk/2011/10/q-with-dr-burt-berkson-low-dose.html
